FDA Approves ACAM2000(TM) Vaccine for Protection Agains...(e company developing novel vaccines that...)

Date:9/3/2007

e company developing novel vaccines that address significant unmet medical needs or substantially improve standards of care. ChimeriVax(TM)-JE, Acambis' most advanced vaccine candidate in its non-biodefense pipeline, has completed Phase 3 trials, and is currently undergoing pediatric trials in India. It is partnered with sanofi pasteur and Bharat Biotech. Acambis' proprietary ChimeriVax technology, developed in association with St Louis University, has also been used to develop Acambis' ChimeriVax-West Nile vaccine candidate, which is undergoing Phase 2 clinical testing, making it the most advanced investigational vaccine against the West Nile virus. Acambis also has the only vaccine in development against Clostridium difficile bacteria, a leading cause of hospital-acquired infections. Acambis' influenza program aims to develop a universal vaccine against influenza, for which a universal 'A' strain vaccine, ACAM-FLU-A(TM), is currently being tested in a Phase 1 trial, and also includes various further vaccine candidates in the research and pre-clinical stages.

Recognised internationally as the leading producer of smallpox vaccines, Acambis manufactured its smallpox vaccine, ACAM2000, for emergency-use stockpiles held by the US Government and 14 others governments around the world under a US FDA IND application. ACAM2000 is licensed for active immunization of persons determined to be at high risk for smallpox infection.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at http://www.acambis.com.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in the news release that are not historical facts are forward-looking statements that involve risks and uncertainties, including the timing and results of clinical trials, product development, manufacturing a
'/>"/>

SOURCE Acambis plc Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. New Mexico firm to make flu vaccine at Wisconsin BioManufacturing facility
9. Studies Offer New Insight into HIV Vaccine Development
10. Protector RNase Inhibitor Enhance the Protection of RNA against Degradation
11. RNase Protection Assay (RPA) Using DIG-Labeled RNA Probes